SEC Form 4 · accession 0001493152-26-027088
ONCOLYTICS BIOTECH INC · ONCY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Aromando
Officer — Chief Business Officer
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001129928
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | $1.06 | Jun 1, 2026 | A | 260,000 | A | — | Jun 1, 2036 | Common Shares | 260,000 | 260,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
- F2The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.